Skip to main content

Identificación de las actividades del complejo IKK con impacto funcional en la resistencia terapéutica del cáncer y la metástasis

PI22/00069

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)
Execution centre FUNDACION INSTITUTO HOSPITAL DEL MAR DE INVESTIGACIONES MEDICAS (FIMIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Cabré-Romans, Júlia-Jié
  • González, Antón
  • Fernández, Lierni
  • Marruecos, Laura|||0000-0002-4206-709X
  • Guix, Marta|||0000-0002-2143-0697
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • López, Sandra
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1. Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients. Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse. Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry

  • Prados de la Torre, Esther
  • Serrano, Josefina
  • Barragán, Eva
  • Ayala, Rosa
  • Calasanz, María José
  • Chillón, María Carmen
  • Soria, Elena
  • Bilbao-Sieyro, Cristina
  • Cabello, Ana
  • Lavilla-Rubira, Esperanza
  • Almela Gallego, Ágata
  • Labrador Gómez, Jorge
  • Pérez-Simón, José A.
  • Rodríguez-Veiga, Rebeca
  • Martínez-Cuadrón, David
  • Vives, Susana
  • Bergua-Burgues, Juan Miguel
  • Ibañez Alis, Francisco
  • Gil, Cristina
  • Algarra, Lorenzo
  • Castaño, Tamara
  • Tormo, Mar
  • Bernal del Castillo, Teresa
  • Martínez Sánchez, María Del Pilar
  • Casado, Marisol
  • Arce Fernández, Olga
  • Herrera-Puente, Pilar
  • Vidriales Vicente, María Belén
  • Colorado, Mercedes
  • Madrigal Toscano, María Dolores
  • González, Bernardo Javier
  • Panero Ruiz, Miriam
  • Olave Rubio, Maite
  • Sánchez-García, Joaquín
  • Montesinos, Pau
The aim of our study was to analyze the incidence, co-mutation pattern, and prognostic impact of CEBPA gene mutations in a large multicenter consecutive series of 1367 adult patients AML patients treated with non-IT modalities. A total of 83 patients (6.1%) had mutations in CEBPA gene. Among these, 34 (2.5%) harbored mutations located in bZIP domain (bZIP in-frame N = 6) and 49 (3.6%) in other regions of the gene (other CEBPAmut). Genes most frequently co-mutated in these CEBPAmut patients were TET2 (45.8%, N = 38), SRSF2 (42.2%, N = 35), and ASXL1 (40.9%, N = 34). Using the Bradley-Terry model we identified that mutations in MDS-related genes, in TP53, and in epigenetic regulators appear to occur earlier. In contrast, genes involved in activating cell signaling appeared to occur later than CEBPAmut. Overall Survival (OS) of non-IT AML patients was analyzed according to the type of CEBPAmut. Median OS was 11.6 months in CEBPA-bZIP patients compared to 9.0 and 6.9 for patients with other CEBPAmut or CEBPAwt, respectively. When selecting 1129 AML patients treated with HMA or HMA-based combinations, CEBPA-bZIP patients had a median survival time of 11.6 months (range 9.6-NR) and 2.5 years survival probability of 20.1% which were outcomes comparable to remaining ELN2024 favorable patients. We concluded that our series of non-IT AML patients within the PETHEMA registry confirm a low percentage of CEBPA mutated cases which are frequently co-mutated with MDS related genes. Those CEBPA-bZIP cases harbor a similar median OS than those belonging to favorable ELN2024 risk category., This investigation was partially supported by Instituto de Salud Carlos III, Spain, grant PMP22/00069 and PI19/00730., Peer reviewed